DualityBio's Advanced HER3 Antibody-Drug Conjugate Receives FDA Fast Track Status for Cancer Treatment DualityBio's DB-1310 HER3-targeting ADC has been granted FDA Fast Track Designation for treating advanced lung cancer, advancing cancer therapy.

DualityBio's Advanced HER3 Antibody-Drug Conjugate Receives FDA Fast Track Status for Cancer Treatment #Shanghai #United_States #Cancer_Treatment #HER3_ADC #DualityBio

Elevation Oncology Reveals First Quarter 2025 Financial Performance and Future Directions Elevation Oncology has shared its first quarter 2025 financial results, highlighting progress in HER3 ADC EO-1022 development and strategic options to enhance shareholder value.

Elevation Oncology Reveals First Quarter 2025 Financial Performance and Future Directions #USA #Boston #Elevation_Oncology #HER3_ADC #EO-1022

Elevation Oncology Unveils Promising EO-1022 Data at AACR Annual Meeting 2025 Elevation Oncology shared compelling preclinical data for EO-1022 at AACR 2025, showcasing its potential as a HER3 ADC in treating solid tumors.

Elevation Oncology Unveils Promising EO-1022 Data at AACR Annual Meeting 2025 #USA #Chicago #Elevation_Oncology #HER3_ADC #EO-1022

Elevation Oncology Reveals Q4 and Full Year 2024 Financial Performance and Corporate Achievements Elevation Oncology announces significant financial outcomes for Q4 and the entirety of 2024, along with major achievements in its cancer treatment programs.

Elevation Oncology Reveals Q4 and Full Year 2024 Financial Performance and Corporate Achievements #United_States #Boston #Elevation_Oncology #EO-3021 #HER3_ADC

Elevation Oncology Accelerates Cancer Treatment Innovations with EO-1022, a New ADC Development Candidate Elevation Oncology has introduced EO-1022, a HER3 ADC aimed at treating solid tumors. This novel candidate showcases advanced technologies for potential cancer therapy breakthroughs.

Elevation Oncology Accelerates Cancer Treatment Innovations with EO-1022, a New ADC Development Candidate #United_States #Boston #Elevation_Oncology #HER3_ADC #EO-1022